Safety

Xyzal (levocetirizine dihydrochloride) oral solution and tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) 

June 2016

Summary View

ADVERSE REACTIONS

Post-Marketing Experience
  • Addition to listing of adverse reactions...arthralgia
  • Replacement of “events” with “reactions” throughout section.

 

November 2013

Summary View

ADVERSE REACTIONS

Post-Marketing Experience
  • movement disorders (including dystonia and oculogyric crisis
  • tic, myoclonus, extrapyramidal symptoms

 

September 2012

Summary View

5 WARNINGS AND PRECAUTIONS

5.2 Urinary Retention
  • Urinary retention has been reported post-marketing....

6 ADVERSE REACTIONS

6.2 Postmarketing Experience
  • added ..... urinary retention

17 PATIENT COUNSELING INFORMATION

 

March 2011 

Summary View

ADVERSE REACTIONS

 Postmarketing Experience
  • vomiting, dysuria, blurred vision, angioedema, paraesthesia, dizziness

 

Page Last Updated: 07/07/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.